Autolus Therapeutics (AUTL) Misses Q1 EPS by 2c, Misses on Revenue; Offers FY26 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 14, 2026 7:00 AM EDTAUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underwayObe-cel clinical development programs on track with trial... More
